Having an evidence package at launch that satisfies payers’ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.
Meadow Green
Advertisement
Articles by Meadow Green
The healthcare market has been consolidating in recent years with practice mergers, hospital partnerships, and acquisitions or affiliations with primary care and specialist practices.
Advertisement
Latest Updated Articles
Doctors May Lose Care Control to Integrated Delivery NetworksPublished: May 9th 2015 | Updated:
Value and Market Access Considerations Often Missing From Trial DesignPublished: January 26th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5